Completed
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
I8F-JE-GPGP - ClinicalTrials.gov - NCT03861039
The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.
How long will I be in the trial?
Your participation could last about 60 weeks and may include up to 14 visits to the study center.
Completed
A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes
I8F-JE-GPGP - ClinicalTrials.gov - NCT03861039
The purpose of this study is to determine the long-term safety of the study drug tirzepatide in combination with oral antihyperglycemic medications in participants with type 2 diabetes.
How long will I be in the trial?
Your participation could last about 60 weeks and may include up to 14 visits to the study center.
Key Requirements
Age :
20+
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
20+
Sex
All
Participants must
Participants must have type 2 diabetes
Participants must have hemoglobin A1c ≥7.0% and ≤11.0%
Participants must have been taking certain medications (sulfonylureas, biguanides, thiazolidinedione, alpha-glucosidase inhibitor, glinides, or sodium-glucose cotransporter type 2 inhibitors) for at least 3 months before screening and have been on the following dose for at least 8 weeks before screening
Participants must have a BMI ≥23 kilograms per meter squared (kg/m2)
Participants must be of stable weight
Participants must NOT
Participants must not have type 1 diabetes
Participants must not have inflammation of the pancreas
Participants must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participants must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Participants must not have been taking weight loss drugs during the last 3 months
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
Tirzepatide
Could I receive a Placebo?
no
Enrollment Goal
441
Trial Dates
March 2019 - February 2021
Trial Phase
3
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
20+
Sex
All
Participants must
Participants must have type 2 diabetes
Participants must have hemoglobin A1c ≥7.0% and ≤11.0%
Participants must have been taking certain medications (sulfonylureas, biguanides, thiazolidinedione, alpha-glucosidase inhibitor, glinides, or sodium-glucose cotransporter type 2 inhibitors) for at least 3 months before screening and have been on the following dose for at least 8 weeks before screening
Participants must have a BMI ≥23 kilograms per meter squared (kg/m2)
Participants must be of stable weight
Participants must NOT
Participants must not have type 1 diabetes
Participants must not have inflammation of the pancreas
Participants must not have had a heart attack, stroke, or hospitalization for congestive heart failure in the past 2 months
Participants must not have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2
Participants must not have been taking weight loss drugs during the last 3 months
Trial Summary
Conditions the trial is for
Adult Type 2 Diabetes
What the trial is testing?
Tirzepatide
Could I receive a Placebo?
no
Enrollment Goal
441
Trial Dates
March 2019 - February 2021
Trial Phase
3
Not the right fit? Sign up to receive updates on new Adult Type 2 Diabetes trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
By clicking the checkbox and using the map, you agree to allow Google Maps to collect your personal information in accordance with their Privacy Policy
Adult Type 2 Diabetes Resources
